Go Deep
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,957 | -5.0 | 3.37 | 0.18 | 1,999.91 |
| Oct 2026 | 20,002 | -4.9 | 3.33 | 0.18 | 1,971.11 |
| Oct 2026 | 19,839 | -5.2 | 3.47 | 0.18 | 2,054.96 |
| Oct 2026 | 20,087 | -4.8 | 3.26 | 0.18 | 1,922.71 |
| Oct 2026 | 19,972 | -5.0 | 3.36 | 0.18 | 1,983.56 |
| Oct 2026 | 19,850 | -5.1 | 3.46 | 0.18 | 2,046.14 |
| Oct 2026 | 19,939 | -5.0 | 3.39 | 0.18 | 1,995.68 |
| Oct 2026 | 19,870 | -5.1 | 3.44 | 0.18 | 2,026.57 |
Mineralys Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -241,071,000.0 | -39,339,000.0 | -32,234,000.0 | -36,932,000.0 |
| EPS | -2.9 | -0.5 | -0.4 | -0.5 |
Mineralys Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -154,651,000.0 | -177,810,000.0 | -71,898,000.0 | -29,799,000.0 | — |
| EPS | -2.3 | -3.7 | -2.0 | -0.8 | — |
Mineralys Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 661,806,000.0 | 205,903,000.0 | 251,636,000.0 | 114,442,000.0 | — |
| Total Liabilities | 15,113,000.0 | 14,646,000.0 | 10,482,000.0 | 166,711,000.0 | — |
| Total Equity | 646,693,000.0 | 191,257,000.0 | 241,154,000.0 | -52,269,000.0 | — |
Owes vs Owns
Mineralys Therapeutics, Inc. owed $0.18 for every $1 it owned in Jun 2026, down from $1.46 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.18× | 0.02× | 0.07× | 0.04× | 1.46× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Mineralys Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 99.2%Other assets 0.8%
How it's funded — Dec 2025
Other liabilities 2.0%Shareholders' equity 97.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 656.6 | 198.2 | 236.6 | 110.1 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.1 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 2.5 | 0.0 |
| Other assets | 5.1 | 7.7 | 12.6 | 4.3 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 2.0 | 0.5 | 0.6 | 1.9 |
| Other liabilities | 13.1 | 14.2 | 9.9 | 164.8 |
| Shareholders' equity | 646.7 | 191.3 | 241.2 | -52.3 |
| Net tangible assets | 646.7 | 191.3 | 241.2 | -52.3 |
Mineralys Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -142,416,000.0 | -166,314,000.0 | -81,173,000.0 | -29,221,000.0 | — |
| Investing Activities | -389,753,000.0 | 114,959,000.0 | -160,472,000.0 | -21,759,000.0 | — |
| Financing Activities | 590,999,000.0 | 116,142,000.0 | 203,248,000.0 | 128,019,000.0 | — |